Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF PROMIMERCE.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it could be a valid.

	trol number.		or 1999, no persons	are required to respond to a conet	ction of information unless is con	Atallis a vally
Substitute for form 1449/PTO			49/PTO	C	Complete if Known	OV 2 5 2008
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	10/567,328	<u> </u>
				Filing Date	8/6/2004	£/
Da	te Submitted:	N	OV 2 5 2008	First Named Inventor	Makoto SAWADA	2 marsh 1
(use as many sheets as necessary)			01 2 0 2000	Art Unit	1649	HADEN
			necessary)	Examiner Name	Stacey Nee MacFarland	е
Sheet	1	of	1	Attorney Docket Number	084335-0201	

Examin er No.1	Cite	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴⁻ Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	E1	WO 03/009881 A2	02/06/2003	Imarx Therapeutics, Inc.		
	E2	WO 03/020751 A2	03/13/2003	King's College London		
						<u> </u>

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶			
	E3	EGLETON et al., "Transport of Opioid Peptides into the Central Nervous System," Journal of Pharmaceutical Sciences, November 1998, 87(11):1433-1439.				
	E4	PIWKO et al., "Localization and Pharmacological Characterization of Somatostatin Recognition Sites in the Human Cerebellum," Neuropharmacology, June 1996, 35(6):713-723.				
			į			

Examiner Signature	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.